The BRCA Founder Outreach (BFOR) study, focusing on individuals of Ashkenazi descent, will give participants the opportunity to receive simpler access to genetic testing.
Healthline reports on recent research showing that many women who experience a bloating feeling on a regular basis are more likely to change their diets than visit their doctors, and in some cases, that could put women at risk of overlooking ovarian cancer symptoms.
Basser Young Leadership Council co-chair Erika Stalings reveals her experiences with dating after undergoing a preventive double mastectomy, and her struggles to decide if and when to tell dates about the surgery and her BRCA mutation status.
Susan M. Domchek, MD, Executive Director of the Basser Center, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.
Genetic counselors, oncologists and other experts are urging consumers to do their homework before sending in saliva samples and allowing their DNA to be screened for certain cancer risks by the company 23andMe.
U.S. consumers soon will be able to test themselves at home for some genetic mutations that increase the risk of breast, ovarian and prostate cancer — but you might want to think before you spit. Susan Domchek, MD, speaks to USA Today about BRCA mutations.
The FDA approved the first oral treatment for breast cancer patients who have inherited mutations in their BRCA genes. Susan Domchek, MD, who was involved in the clinical trial, discusses how this is a major step forward.
Penn Medicine Magazine
Penn Medicine Magazine's latest issue includes the story of how the Basser Center was founded in memory of Faith Basser, and how BRCA mutations can impact families around the world.
The U.S. Food and Drug Administration recently approved olaparib as the first treatment for advanced breast cancer caused by mutations in BRCA genes, in an important step in the fight against inherited cancers.
Susan Domchek, MD, Executive Director of the Basser Center, discussed the evolving treatment landscape for patients with BRCA-related, metastatic breast cancer.
Last week, journalist Joan Lunden moderated a panel of experts, “Knowledge is Power: Understanding and Managing BRCA-Related Cancer Risk.” The program, co-presented by the Basser Center, focused on the latest lifesaving information surrounding BRCA-related cancers.
Basser Center co-founder Mindy Gray's family is in the news, thanks to her inspiring father, Phil Basser, whose love of the Eagles has gone viral just before his 100th birthday.
OncLive reports on recent Penn-led research showing that the combination of olaparib and durvalumab demonstrated a disease control rate of 80 percent for pretreated patients with germline BRCA-mutated, HER2- negative metastatic breast cancer.
Good Morning America
TeloYears is an at-home test that promises to reveal a user's true biological age by measuring telomeres, the ends of chromosomes that wear down over time. Susan Domchek, MD, advised caution, saying there has to be more study.
The biennial Basser Jean Bash celebrated five years of progress toward understanding, treating and preventing hereditary cancers. The benefit honored Raquel and Michael Hass and Pulitzer Prize-winning author Siddhartha Mukherjee, MD, DPhil.
Basser's Angela Bradbury, MD, says one of the biggest challenges is that many patients don't have access to genetic counselors.
Forbes takes a deep dive into the use of PARP inhibitors in the fight against pancreatic cancer, which features a recently opened trial led by Kim A. Reiss Binder, MD, an assistant professor of Hematology Oncology.
A local woman and her family discuss how they have been affected by cancers caused by a PALB2 gene mutation, a gene that works to repair broken strands of DNA. Like BRCA, it potentially increases an individual's risk of certain cancers.